Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. It offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by Take Shape for Life, and Flavors of Home brands. The company markets its products through point of sale transactions over ecommerce platform and its franchisee system. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.
IPO Year:
Exchange: NYSE
Website: medifastinc.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/5/2024 | $16.50 → $17.00 | Underperform → Neutral | DA Davidson |
| 6/5/2024 | $25.00 → $17.50 | Neutral → Underperform | DA Davidson |
| 10/13/2023 | $82.00 | Equal-Weight | Stephens |
| 11/4/2022 | $278.00 → $106.00 | Buy → Neutral | DA Davidson |
| 8/4/2022 | $345.00 → $150.00 | Buy → Hold | Jefferies |
| 2/24/2022 | $349.00 → $341.00 | Buy | DA Davidson |
| 11/8/2021 | $395.00 → $349.00 | Buy | DA Davidson |
10-Q - MEDIFAST INC (0000910329) (Filer)
8-K - MEDIFAST INC (0000910329) (Filer)
S-8 - MEDIFAST INC (0000910329) (Filer)
10-Q - MEDIFAST INC (0000910329) (Filer)
8-K - MEDIFAST INC (0000910329) (Filer)
8-K - MEDIFAST INC (0000910329) (Filer)
ARS - MEDIFAST INC (0000910329) (Filer)
10-Q - MEDIFAST INC (0000910329) (Filer)
8-K - MEDIFAST INC (0000910329) (Filer)
DEF 14A - MEDIFAST INC (0000910329) (Filer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S
BALTIMORE, March 2, 2023 /PRNewswire/ -- Medifast (NYSE:MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, today announced it has named Steven Zenker as Vice President of Investor Relations. Mr. Zenker has over 30 years of investor relations, financial planning and analysis, communications, and investment management experience. He reports to Chief Financial Officer Jim Maloney and will lead the strategy and continued implementation of the company's investor relations program. "We are pleased to welcome Steven to the Medifast t
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the third quarter ended September 30, 2024. Third Quarter 2024 Revenue of $140.2 million, with revenue per active earning coach of $4,672 Independent active earning OPTAVIA coaches of 30,000 Net income of $1.1 million (non-GAAP adjusted net income of $3.9 million) Income per diluted share of $0.10 (non-GAAP adjusted earnings per share ("EPS") of $0.35) Cash, Cash Equivalents, and Investment Securities of $170.0 million with no debt "Medical innovation has transformed the weight loss industry, so at Medifast we're creating a hea
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on November 4, 2024. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or dire
Medifast (NYSE:MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the second quarter ended June 30, 2024. Second Quarter 2024 Revenue of $168.6 million, with revenue per active earning Coach of $4,972 Independent active earning OPTAVIA Coaches of 33,900 Net loss of $8.2 million (non-GAAP adjusted net income of $10.1 million) Loss per diluted share of $0.75 (non-GAAP adjusted earnings per share ("EPS") of $0.92) Cash, Cash Equivalents, and Investment Securities of $163.5 million with zero debt "We are acting decisively to transform our business to position us for long-term growth, with
Medifast (NYSE:MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the second quarter ended June 30, 2024 on Monday, August 5, 2024, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on August 5, 2024. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or directly at
Medifast (NYSE:MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the first quarter ended March 31, 2024. First Quarter 2024 Revenue of $174.7 million, with revenue per active earning coach of $4,623 Independent active earning OPTAVIA Coaches of 37,800 Net income of $8.3 million (non-GAAP adjusted net income of $7.2 million) Earnings per diluted share ("EPS") of $0.76 (non-GAAP adjusted EPS of $0.66) Cash, Cash Equivalents, and Investment Securities of $156.4 million with zero debt "Fast paced medical innovation is providing greater access to medical weight loss solutions than ever bef
Medifast (NYSE:MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the first quarter ended March 31, 2024 on Monday, April 29, 2024, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on April 29, 2024. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or directly at
Medifast (NYSE:MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Revenue of $191.0 million, with revenue per active earning Coach of $4,648 Independent active earning OPTAVIA Coaches of 41,100 Net income of $6.0 million (non-GAAP adjusted net income of $11.9 million) Earnings per diluted share ("EPS") of $0.55 (non-GAAP adjusted EPS of $1.09) Full Year 2023 Revenue of $1.1 billion Net income of $99.4 million (non-GAAP adjusted net income of $105.2 million) EPS of $9.10 (non-GAAP adjusted EPS of $9.64)
Medifast (NYSE:MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the fourth quarter and full year ended December 31, 2023 on Tuesday, February 20, 2024, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on February 20, 2024. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.Medif
Health and wellness company makes $20 million capital commitment to LifeMD, enters medically supported weight loss market projected to reach up to $100 billion by 2030 Company discontinues quarterly cash dividend and intends to invest in initiatives aimed at driving customer acquisition and customer experience to reignite growth Conference call to discuss Medifast and LifeMD collaboration begins at 10 AM EST today Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, today launched the first phase of its business transformation, as part of its commitment to providing comprehensive health and wellness solutions to c
Collaboration will integrate LifeMD's telehealth platform and GLP-1 offering for medically qualified patients with OPTAVIA Coach-guided, healthy lifestyle solution Medifast has invested $20 million, including a $10 million payment in support of the collaboration and a $10 million purchase of LifeMD common stock Conference call to discuss LifeMD and Medifast collaboration begins at 10:00 AM EST today NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc.TM (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced a strategic alliance with Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA
SC 13G/A - MEDIFAST INC (0000910329) (Subject)
SC 13G - MEDIFAST INC (0000910329) (Subject)
SC 13G/A - MEDIFAST INC (0000910329) (Subject)
SC 13G/A - MEDIFAST INC (0000910329) (Subject)
SC 13G/A - MEDIFAST INC (0000910329) (Subject)
SC 13G/A - MEDIFAST INC (0000910329) (Subject)
SC 13G/A - MEDIFAST INC (0000910329) (Subject)
SC 13G/A - MEDIFAST INC (0000910329) (Subject)
SC 13G/A - MEDIFAST INC (0000910329) (Subject)
SC 13G/A - MEDIFAST INC (0000910329) (Subject)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
DA Davidson upgraded Medifast from Underperform to Neutral and set a new price target of $17.00 from $16.50 previously
DA Davidson downgraded Medifast from Neutral to Underperform and set a new price target of $17.50 from $25.00 previously
Stephens initiated coverage of Medifast with a rating of Equal-Weight and set a new price target of $82.00
DA Davidson downgraded Medifast from Buy to Neutral and set a new price target of $106.00 from $278.00 previously
Jefferies downgraded Medifast from Buy to Hold and set a new price target of $150.00 from $345.00 previously
DA Davidson reiterated coverage of Medifast with a rating of Buy and set a new price target of $341.00 from $349.00 previously
DA Davidson reiterated coverage of Medifast with a rating of Buy and set a new price target of $349.00 from $395.00 previously
DA Davidson reiterated coverage of Medifast with a rating of Buy and set a new price target of $395.00 from $302.00 previously
DA Davidson reiterated coverage of Medifast with a rating of Buy and set a new price target of $302.00 from $239.00 previously
DA Davidson reiterated coverage of Medifast with a rating of Buy and set a new price target of $302.00 from $239.00 previously
While 8 out of 10 U.S. adults trying to lose weight are eager to reach their goal as soon as possible, they agree that weight loss is an ongoing process requiring consistent attention and effort* Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, today shared findings from a recent independent survey. Commissioned by Medifast and conducted by the third-party market research firm Talker Research, the goal of the survey was to better understand American perceptions of weight loss medications and their role in health journeys, while also identifying areas where further support is necessary. The survey of 2,000 nation
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the third quarter ended September 30, 2024. Third Quarter 2024 Revenue of $140.2 million, with revenue per active earning coach of $4,672 Independent active earning OPTAVIA coaches of 30,000 Net income of $1.1 million (non-GAAP adjusted net income of $3.9 million) Income per diluted share of $0.10 (non-GAAP adjusted earnings per share ("EPS") of $0.35) Cash, Cash Equivalents, and Investment Securities of $170.0 million with no debt "Medical innovation has transformed the weight loss industry, so at Medifast we're creating a hea
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on November 4, 2024. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or dire
Medifast (NYSE:MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the second quarter ended June 30, 2024. Second Quarter 2024 Revenue of $168.6 million, with revenue per active earning Coach of $4,972 Independent active earning OPTAVIA Coaches of 33,900 Net loss of $8.2 million (non-GAAP adjusted net income of $10.1 million) Loss per diluted share of $0.75 (non-GAAP adjusted earnings per share ("EPS") of $0.92) Cash, Cash Equivalents, and Investment Securities of $163.5 million with zero debt "We are acting decisively to transform our business to position us for long-term growth, with
Medifast (NYSE:MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the second quarter ended June 30, 2024 on Monday, August 5, 2024, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on August 5, 2024. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or directly at
Company recognized as one of the best employers in the food and drink industry for 2024-2025 Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, today announced that it has been recognized in the 2024-2025 rankings by U.S. News & World Report as one of the nation's "Best Companies to Work For" in the food and drink industry. This recognition marks Medifast's second straight year of inclusion on the list and underscores the company's ongoing commitment to creating an outstanding workplace culture and enhancing the lives of its employees and customers. "Being recognized once again as a top workplace highlights the un
NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S
GLP-1 Lifestyle Program brings together clinician-prescribed medications, coach support and new GLP-1 Nutrition Support Kit designed for medication users National advertising campaign with planned $30 million investment intended to drive customer acquisition Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, today announced the launch of the first phase of its multimillion-dollar national marketing campaign. The campaign will highlight OPTAVIA's new offering in collaboration with LifeMD®, the GLP-1 Lifestyle Program, a holistic approach to medical weight loss specifically tailored to support the needs of those uti
Medifast (NYSE:MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the first quarter ended March 31, 2024. First Quarter 2024 Revenue of $174.7 million, with revenue per active earning coach of $4,623 Independent active earning OPTAVIA Coaches of 37,800 Net income of $8.3 million (non-GAAP adjusted net income of $7.2 million) Earnings per diluted share ("EPS") of $0.76 (non-GAAP adjusted EPS of $0.66) Cash, Cash Equivalents, and Investment Securities of $156.4 million with zero debt "Fast paced medical innovation is providing greater access to medical weight loss solutions than ever bef
Medifast (NYSE:MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the first quarter ended March 31, 2024 on Monday, April 29, 2024, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on April 29, 2024. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or directly at